Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VERVE 101

Next Previous
Drug Profile

VERVE 101

Alternative Names: VERVE-101

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Broad Institute; Harvard University
  • Developer Verve Therapeutics
  • Class Antihyperlipidaemics; RNA
  • Mechanism of Action Gene modulators; PCSK9 protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperlipoproteinaemia type IIa

Most Recent Events

  • 14 Feb 2025 Verve Therapeutics completes a phase-I clinical trials in Hyperlipoproteinaemia type IIa (In adults, In the elderly) in New Zealand, United Kingdom (IV) (NCT05398029)
  • 12 Nov 2023 US FDA approves IND application for VERVE 101 in Hyperlipoproteinaemia type IIa, prior to November 2023
  • 31 Oct 2023 Beam Therapeutics enters into a collaboration agreement with Eli Lilly for PCSK9 and ANGPTL3 programs including VERVE 101

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top